Table 2.

Thromboembolic and bleeding events during 3 years of follow-up

Adverse event	Total	Anticoagulation therapy‡, n	Antiplatelet therapy‡, n	No antiplatelet or anticoagulant therapy, n
Thromboembolism, n (%)	33 (8.8)	14	16	3
Myocardial infarction	12 (3.2)	8	4	0
Stroke/TIA	14 (3.7)∗	4	8	2
Other thromboembolism	7 (1.9)	2	4	1
Bleeding, n (%)	33 (8.8)†	32	14	0
Major	21 (5.6)	21	8	0
CRNMB	12 (3.2)	11	6	0

CRNMB, clinically relevant nonmajor bleeding; TIA, transient ischemic attack.

^∗13 patients had 14 events.

^†25 patients had 33 events.

^‡Some patients were both on anticoagulation and antiplatelet therapy.